RecruitingNot Applicable

A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Austria2,000 participantsStarted 2025-02-12

Plain-language summary

Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Written informed consent to participate
✓. At least 18 years of age
✓. High and very high risk patients as assessed by the physician suffering from documented primary hypercholesterolemia or mixed dyslipidemia at start of bempedoic acid treatment
✓. Patients treated with:

Exclusion criteria

✕. Patients who have received PCSK9i monoclonal antibody treatment in the last 3 months before the start of the triple therapy exposure
✕. Patients who have ever received PCSK9i-siRNA treatment

What they're measuring

Relative LDL-C change between untreated and 8 week after triple therapy start

Timeframe: Baseline to 8 weeks after initiation of triple therapy

Trial details

NCT IDNCT06686615

SponsorDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-07-31

Contact for this trial

Daiichi Sankyo Contact for Clinical Trial Information

9089926400 CTRinfo_us@daiichisankyo.com

View on ClinicalTrials.gov More Primary Hypercholesterolemiia trials